Long-term survival after surgical management of neuroendocrine hepatic metastases

LAUR Repository

Show simple item record

dc.contributor.author Glazer, Evan
dc.contributor.author Tseng, Jennifer
dc.contributor.author Al-Refaie, Waddah
dc.contributor.author Solorzano, Carmen
dc.contributor.author Liu, Ping
dc.contributor.author Willborn, Katherine
dc.contributor.author Abdalla, Eddie
dc.contributor.author Vauthey, Jean-Nicolas
dc.date.accessioned 2015-11-19T08:09:23Z
dc.date.available 2015-11-19T08:09:23Z
dc.date.copyright 2010
dc.date.issued 2015-11-19
dc.identifier.issn 1365-182X en_US
dc.identifier.uri http://hdl.handle.net/10725/2615
dc.description.abstract Background:  Surgical cytoreduction and endocrine blockade are important options for care for neuroendocrine liver metastases. We investigated the long-term survival of patients surgically treated for hepatic neuroendocrine metastases. Methods:  Patients (n= 172) undergoing operations for neuroendocrine liver metastases from any primary were identified from a prospective liver database. Recorded data and medical record review were used to analyse the type of procedure, length of hospital stay, peri-operative morbidity, tumour recurrence, progression,and survival. Results:  The median age was 56.8 years (range 11.5–80.7 years). 48.3% of patients were female. Median overall survival was 9.6 years (range 89 days to 22 years). On multivariate analysis, lung/thymic primaries were associated with worse survival [hazard ratio (HR): 15.6, confidence interval (CI): 4.3–56.8, P= 0.002]. Severe post-operative complications were also associated with worse long-term survival (P < 0.001). A positive resection margin status (R1) was not associated with a worse overall survival probability (P∼ 0.8). Discussion:  Early and aggressive surgical management of hepatic metastases from neuroendocrine tumours is associated with significant long-term survival rates. Radiofrequency ablation is a reasonable option if a lesion is unresectable. R1 resections, unlike many other cancers, are not associated with a worse overall survival. en_US
dc.language.iso en en_US
dc.title Long-term survival after surgical management of neuroendocrine hepatic metastases en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal HBP en_US
dc.journal.volume 12 en_US
dc.journal.issue 6 en_US
dc.article.pages 427-433 en_US
dc.keywords Neuroendocrine en_US
dc.keywords Carcinoid en_US
dc.keywords Liver metastases en_US
dc.keywords Liver resection en_US
dc.keywords Radiofrequency ablation en_US
dc.keywords Survival en_US
dc.identifier.doi http://dx.doi.org/10.1111/j.1477-2574.2010.00198.x en_US
dc.identifier.ctation Glazer, E. S., Tseng, J. F., Al‐Refaie, W., Solorzano, C. C., Liu, P., Willborn, K. A., ... & Curley, S. A. (2010). Long‐term survival after surgical management of neuroendocrine hepatic metastases. Hpb, 12(6), 427-433. en_US
dc.author.email eddie.abdalla@lau.edu.lb

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account